Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells

Blood

Volumn 88, Issue 3, 1996, Pages 977-984

  Frank, Adrian J ^b   Proctor, Stephen J ^b   Tilby, Michael J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; MELPHALAN; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DNA ADDUCT; DNA CONTENT; DRUG DNA INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; TUMOR CELL CULTURE;

EID: 0029744782     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.977.977     Document Type: Article

References (37)

1. Jasmin C, Charpentier A, Marion S, Proctor SJ: Concepts of remission, curability and lineage involvement in relationship to the problems of minimal residual leukemia. Baillieres Clin Haematol 4:599, 1991
2. Greaves MF: Stem cell origins of leukemia and curability. Br J Cancer 67:412, 1993
3. Hall AG, Tilby MJ: Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of hematological malignancies. Blood Rev 6:163, 1992
4. Lawley PD, Phillips DH: DNA adducts from chemotherapeutic agents. Mutat Res 1996 (in press)
5. Tilby MJ, Styles JM, Dean CJ: Immunological detection of DNA caused by melphalan using monoclonal antibodies. Cancer Res 47:1542, 1987
6. Tilby MJ, McCartney H, Cordell J, Frank AJ, Dean CJ: A monoclonal antibody that recognizes alkali-stabilized melphalan-DNA adducts and its application in immunofluorescence microscopy. Carcinogenesis 16:1895, 1995
7. Osborne MR, Lawley PD: The reaction of melphalan with deoxyguanosine and deoxyguanylic acid. Chem Biol Interact 84:189, 1992
8. Osborne MR, Lawley PD: Alkylation of DNA by melphalan with special reference to adenine derivatives and adenine-guanine cross-linking. Chem Biol Interact 89:49, 1993
9. Tilby MJ, Lawley PD, Farmer PB: Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: Characterization of monoalkylated and cross-linked products from reaction of melphalan with dGMP and GMP. Chem Biol Interact 73:183, 1990
10. Tilby MJ, Newell DR, Viner C, Selby PJ, Dean CJ: Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of a patient undergoing high-dose melphalan therapy. Eur J Cancer 29A:681, 1993
11. Welters MJP, Braakhuis BJM, Schuurman JH, Tilby MJ, Fichtinger-Schepman A-MJ: Sensitivity of human head and neck tumors to cisplatin in relation to cisplatin-DNA -adduct levels. Proceedings of the seventh International Symposium on platinum and other metal coordination compounds in cancer chemotherapy, Amsterdam, The Netherlands, March 1995 (abstr)
12. Blommaert FA, Michael C, Terheggen PMAB, Muggiam FM, Kortes V, Schomagel JH, Hart AAM, den Engelse L: Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: Inter-individual variation and correlation with disease response. Cancer Res 53:5669, 1993
13. Fichtinger-Schepman A-MJ, van Dijk-Knijnenburg HCM, Mars-Groenendijk RH, van der Wulp CJM, Tilby MJ, Berends F, Baan RA: Characterization and quantification of DNA platination by cisplatin and carboplatin by in situ immunofluorescence microscopy, ELISA and alkaline elution. Proc Am Assoc Cancer Res 33:5, 1992 (abstr)
14. Terheggen PMAB, Emondt JY, Floot BGJ, Dijkman R, Schrier PI, den Engelse L, Begg AC: Correlation between cell killing by cis-diamminedichloroplatinum (II) in six mammalian cell lines and binding of cis-diamminedichloroplatinum (II)-DNA antiserum. Cancer Res 50:3556, 1990
15. Terheggen PMAB, Dijkman R, Begg AC, Dubbelman R, Floot BGJ, Hart, AAM, den Engelse L: Monitoring of interaction of cis-diamminedichloroplatinum (II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum (II) with DNA in cells from platinum-treated cancer patients. Cancer Res 48:5597, 1988
16. Terheggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman A-MJ, den Engelse L: Immunocytological detection of interaction products of cis-diamminedichloroplatinum (II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum (II) with DNA in rodent tissue sections. Cancer Res 47:6719, 1987
17. 6-alkylguanines in the nuclear DNA of human lymphocytes and leukemia cells: Analysis at the single-cell level. Br J Cancer 69:698, 1994
18. Seiler F, Kirstein U, Eberle G, Hochleitner K, Rajewsky MF: Quantification of specific DNA-alkylation products in individual cells by monoclonal antibodies and digital imaging of intensified nuclear fluorescence. Carcinogenesis 14:1907, 1993
19. Motykiewicz G, Malusecka E, Grzybowska E, Chorazy M, Zhang Y-J, Perera FP, Santella RM: Immunohistochemical quantitation of polycyclic aromatic hydrocarbon-DNA adducts in human lymphocytes. Cancer Res 55:1417, 1995
20. Tilby MJ, Johnson C, Knox RJ, Cordell J, Roberts JJ, Dean CJ: Sensitive detection of DNA modifications induced by cisplatin and carboplatin in-vitro and in-vivo using a monoclonal antibody. Cancer Res 15:123, 1991
21. Noesis, Visilog 4: A tutorial on Image Processing. Manchester Computing Centre, CHEST, 1993
22. Robson CN, Alexander J, Harris AL, Hickson, ID: Isolation and characterization of a chinese hamster ovary cell line resistant to bifunctional nitrogen mustards. Cancer Res 46:6290, 1986
23. Hansonn J, Lewensohn R, Ringborg U, Nilsson B: Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 47:2631, 1987
24. Ross WE, Ewig RAG, Kohn KW: Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res 38:1502, 1978
25. Alaoui-Jamali MA, Panasci L, Centurioni GM, Schexter R, Lehnert S, Batist G: Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferace activity. Cancer Chemother Pharmacol 30:341, 1992
26. Fairbairn DW, Olive PL, O'Neill KL: The comet assay: A comprehensive review. Mutat Res 339:37, 1995
27. Olive PL, Wlodek D, Durand RE, Banath JP: Factors influencing DNA migration from individual cells subjected to gel electrophoresis. Exp Cell Res 198:259, 1992
28. Wild CP: Antibodies to DNA alkylation adducts as analytical tools in chemical carcinogenesis. Mutat Res 233:219, 1990
29. Poirier MC: Antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA: Application for detection of xenobiotics in biological samples. Mutat Res 288:31, 1988
30. Santella RM: Application of new techniques for the detection of carcinogen adducts to human population monitoring. Mutat Res 205:271, 1988
31. Gould KA, M'Cartney H, Lawley PD, Golding BT, Tilby MJ: The role of p53 in the anti-cancer effect of alkylating agents: p53 induction by measured levels of specific DNA adducts. Br J Cancer 73:39, 1996 (abstr, suppl XXVI)
32. Tilby MJ, McCartney H, Cordell J, Dean CJ: Novel monoclonal antibodies for the analysis of melphalan-DNA adducts in cells. Br J Cancer 69:32, 1994 (suppl XXI)
33. Tattersall MHN, Jarman M, Newlands ES, Holyhead L, Milstead RAV, Weinberg A: Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease. Eur J Cancer 14:507, 1978
34. Vistica DT: Cytotoxicity as an indicator for transport mechanisms: Evidence that murine progenitor cells lack a high-affinity leucine carrier that transports melphalan in murine L1210 leukemia cells. Blood 56:427, 1980
35. Dive C, Hickman JA: Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64:197, 1991
36. Frank AJ, Tilby MJ: Measurement of melphalan DNA adducts in individual multiple myeloma cells using a novel immunofluorescence staining technique and image analysis. Proc Am Assoc Cancer Res 37:174, 1996
37. Sviland L, Leggat H, Harris AL, Bird G, Proctor SJ: Short course intermediate dose intravenous melphalan therapy in myeloma-relation to emergence of drug resistance (phase II study). Acta Hematol 78:233, 1987